Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Dermatologic 2Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 4Lung Neoplasms 4Prostatic Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumors 3Urinary Bladder Neoplasms 2Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Head and Neck Neoplasms 2Biliary Tract Neoplasms 2Urothelial Cancer 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × tremelimumab × Clear all
NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

GlaxoSmithKline

Phase 1/2 Completed
26 enrolled 47 charts
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

AstraZeneca

Phase 2 Completed
37 enrolled 13 charts
DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT00372853 2012-06-06

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

AstraZeneca

Phase 1 Completed
28 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡